Quick Answer
Disc Medicine, Inc. reported Research And Development Expense of $170.64 million for the year ending 2025.
- Disc Medicine, Inc. showed an increase of +76.5% in Research And Development Expense from 2024 to 2025.
- This data is from Disc Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $8.22 million | Q2 2020: $5.53 million | Q3 2020: $6.73 million | Q1 2021: $11.79 million | Q2 2021: $10.84 million | Q3 2021: $13.46 million | Q1 2022: $7.82 million | Q2 2022: $7.71 million | Q3 2022: $7.89 million | Q1 2023: $20.18 million | Q2 2023: $12.10 million | Q3 2023: $14.42 million | Q1 2024: $23.70 million | Q2 2024: $23.49 million | Q3 2024: $24.69 million | Q1 2025: $27.76 million | Q2 2025: $46.32 million | Q3 2025: $50.33 million.
- Over the full 6 years of available data (2020 to 2025), Disc Medicine, Inc.'s Research And Development Expense has grown by 505.8%.
- Historical annual values: Fiscal year 2025: $170.64 million | Fiscal year 2024: $96.67 million | Fiscal year 2023: $69.26 million | Fiscal year 2022: $33.44 million | Fiscal year 2021: $25.17 million | Fiscal year 2020: $28.17 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: